《美国临床皮肤病学杂志》通过发表涵盖皮肤病管理各个方面的批判性和综合性评论文章和以临床为重点的原创研究文章，促进皮肤病学学科内的循证治疗和有效的患者管理。美国临床皮肤病学杂志提供一系列额外的增强功能，旨在提高期刊内容的知名度、读者群和教育价值。每篇文章都附有一个关键点摘要，为广大读者提供了一个省时的内容概述。文章可能附有简单的语言摘要，以帮助患者、护理人员和其他人了解重要的医学进展。该杂志还提供了包含各种其他类型的增强功能的选项，包括幻灯片、视频和动画。所有增强功能都经过同行评审，达到与文章本身相同的高标准。同行评审是使用由国际专家数据库支持的 EDITORIAL MANAGER® 进行的。该数据库与其他 ADIS 期刊共享。

The American Journal of Clinical Dermatology aims to promote evidence-based treatment and effective patient management in the field of dermatology by publishing critical and comprehensive review articles, as well as clinically focused original research covering all aspects of skin disease management. The journal offers a range of additional enhancement features designed to increase the visibility, readership, and educational value of its content. Each article includes a key point summary, providing readers with a time-saving overview of the content. Articles may also include plain language summaries to help patients, caregivers, and others understand important medical advancements. The journal also provides options for various other types of enhancement features, including slides, videos, and animations. All enhancement features undergo peer review to meet the same high standards as the articles themselves. The peer review process is conducted using the EDITORIAL MANAGER®, supported by an international expert database that is shared with other ADIS journals.

《美国临床皮肤病学杂志》致力于通过发表涵盖皮肤病管理各个方面的批判性和综合性评论文章，以及以临床为重点的原创研究，推动皮肤病学领域的循证治疗和有效患者管理。该杂志提供多种增强功能，旨在提高期刊内容的知名度、读者群和教育价值。每篇文章都附有关键点摘要，方便读者快速了解内容。此外，文章可能还附有简单的语言摘要，以帮助患者、护理人员及其他相关人士理解重要的医学进展。杂志还提供包括幻灯片、视频和动画在内的多种增强功能选项，所有这些内容均经过同行评审，确保达到与文章本身相同的高标准。同行评审过程使用由国际专家数据库支持的 EDITORIAL MANAGER® 进行，该数据库与其他 ADIS 期刊共享。

American Journal of Clinical Dermatology

Rosacea is a chronic inflammatory dermatosis mainly affecting the cheeks, nose, chin, and forehead. Rosacea is characterized by recurrent episodes of flushing or transient erythema, persistent erythema, phymatous changes, papules, pustules, and telangiectasia. The eyes may also be involved. Due to rosacea affecting the face, it has a profound negative impact on quality of life, self-esteem, and well-being. In addition to general skin care, there are several approved treatment options available for addressing these features, both topical and systemic. For some features, intense pulse light, laser, and surgery are of value. Recent advances in fundamental scientific research have underscored the roles of the innate and adaptive immune systems as well as neurovascular dysregulation underlying the spectrum of clinical features of rosacea. Endogenous and exogenous stimuli may initiate and aggravate several pathways in patients with rosacea. This review covers the new phenotype-based diagnosis and classification system reflecting pathophysiology, and new and emerging treatment options and approaches. We address new topical and systemic formulations, as well as recent evidence on treatment combinations. In addition, ongoing studies investigating novel therapeutic interventions will be summarized.

Esther J. van Zuuren

Bernd W. M. Arents

Mireille M. D. van der Linden

Sofieke Vermeulen

Zbys Fedorowicz

Jerry Tan

Am J Clin Dermatol

Rosacea: New Concepts in Classification and Treatment

玫瑰痤疮：分类与治疗的新概念

Rosacea fulminans is a rare inflammatory condition of the central face marked by the abrupt onset of erythematous coalescing papules, pustules, nodules, and draining sinuses. Due to infrequent reporting in the literature, the pathophysiology, classification, and nomenclature of this condition remain controversial. This comprehensive review evaluated a total of 135 cases of rosacea fulminans for clinical and histopathologic features and reported treatment strategies. Patients were 91% female with an average age of onset of 31.3 years. Only 19% of cases reported duration of symptoms longer than 3 months, and reports of recurrence were uncommon. A majority of patients had history of rosacea or flushing, and common triggers included hormonal shifts, emotional stress, and medications. Extrafacial or systemic involvement was rare. Though oral and topical antibiotics were frequently utilized to treat rosacea fulminans, there was a clear shift in reported treatments for rosacea fulminans following the introduction of isotretinoin use in 1987, marked by increased reliance on isotretinoin in addition to topical and systemic corticosteroids. Newer treatments were associated with superior improvement compared with antibiotic monotherapy, most notably dramatically reduced rates of scarring, though reduced rates of disease recurrence were not evident. Several patterns revealed through this review reinforce the classification of rosacea fulminans as a severe yet distinct variant of rosacea and highlight key distinguishing clinical features and treatment options for optimal management.

Rabina K Walsh

Alyson A Endicott

Kanade Shinkai

American journal of clinical dermatology

Diagnosis and Treatment of Rosacea Fulminans: A Comprehensive Review.

暴发性酒渣鼻的诊断与治疗：全面综述

Changes in nail color can provide important clues of underlying systemic and skin disease. In particular, white discoloration (leukonychia) has a high prevalence with a wide array of potential relevant causes, from simple manicure habits to life-threatening liver or kidney failure. Therefore, a reliable assessment of the patient with leukonychia is essential. In the past, two classifications for leukonychia have been presented. The morphological classifies the nail according to the distribution of the white lines: total, partial, transversal, and longitudinal leukonychia. Mees’ and Muehrcke’s lines are examples of transversal leukonychia, while Terry’s and Lindsay’s nails are examples of total and partial leukonychia. The anatomical classifies according to the structure responsible for the white color: the nail plate in true leukonychia, the nail bed in apparent leukonychia, and the surface only in pseudoleukonychia. In this review, both morphological and anatomical features have been combined in an algorithm that enables clinicians to approach leukonychia efficiently and effectively.

Matilde Iorizzo

Michela Starace

Marcel C. Pasch

Leukonychia: What Can White Nails Tell Us?

白甲症：白色指甲能告诉我们什么？

Porokeratosis (PK) is a rare skin disease of unknown etiology. It consists of a keratinization disorder, which may appear in several clinical forms and can undergo malignant transformation. The histopathological hallmark of PK is the cornoid lamella. While many topical, systemic, and surgical treatment modalities for PK have been described, no randomized controlled trials have been performed yet. Because of a lack of treatment standards for PK, European and international guidelines cannot be created.

Till Weidner

Tanja Illing

Diana Miguel

Peter Elsner

Treatment of Porokeratosis: A Systematic Review.

汗孔角化症的治疗：系统综述。

Vitiligo is a chronic autoimmune disease characterized by loss of pigment of the skin, affecting 0.5-2% of the population worldwide. It can have a significant impact on patients' quality of life. In recent years, there has been significant progress in our understanding of the pathogenesis of vitiligo. It is believed that vitiligo develops due to a complex combination of genetics, oxidative stress, inflammation, and environmental triggers. Conventional treatments include camouflage, topical corticosteroids, topical calcineurin inhibitors, oral corticosteroids, phototherapy, and surgical procedures, with the treatment regimen dependent on the patient's preferences and characteristics. With increased understanding of the importance of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway in the pathogenesis of vitiligo, treatment has expanded to include the first US FDA-approved cream to repigment patients with vitiligo. This review summarizes our understanding of the major mechanisms involved in the pathogenesis of vitiligo and its most common available treatments.

Kaitlynne N Cunningham

David Rosmarin

Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors.

白癜风治疗：当前治疗模式与JAK抑制剂的综述

Melanoma, a highly aggressive form of skin cancer, has seen significant advancements in treatment through the introduction of immunotherapy. However, the variability in patient responses underscores the need for reliable biomarkers to guide treatment decisions. This article reviews key biomarkers in melanoma immunotherapy, such as PD-L1 expression, tumor mutational burden (TMB), and gene expression profiles (GEPs). It also explores emerging biomarkers, including LAG-3 expression, immune cell phenotyping in tissue and blood, gut microbiota, and circulating tumor DNA (ctDNA). Notably, ctDNA may offer valuable insights into the efficacy of T cell-engaging bispecific molecules, such as tebentafusp. The review provides a comprehensive overview of the evolving landscape of melanoma biomarkers, their role in personalizing treatment, and future research directions, including neoadjuvant immune checkpoint inhibition.

Robin Reschke

Alexander H. Enk

Jessica C. Hassel

Prognostic Biomarkers in Evolving Melanoma Immunotherapy

进展期黑色素瘤免疫治疗中的预后生物标志物

In this review, we discuss recent developments in our understanding of frontal fibrosing alopecia, a disease that has become increasingly common and widespread since its first description in 1994. An inherited predisposition to frontal fibrosing alopecia, previously suspected from the occurrence of familial cases, has been confirmed through genetic studies. Nevertheless, the epidemiology continues to implicate environmental factors in the aetiology. The search has focussed mainly on personal skin care products such as facial moisturisers and UV filters, and there is also some evidence implicating exogenous oestrogens, but confirmation of direct causal links has so far proved elusive. The pathologic mechanisms underlying follicular deletion are being clarified, including the nature of the inflammatory component, the loss of follicular immune privilege in the bulge region and the role of epithelial-mesenchymal transition in the scarring process. Lichen planus pigmentosus, a common accompaniment to frontal fibrosing alopecia in those with darker skin, is probably a feature of the same pathology affecting interfollicular epidermis, rather than a co-morbidity, and may offer new clues to the aetiology. Treatment is still based largely on retrospective case series and variable endpoints. However, methods for assessing frontal fibrosing alopecia and monitoring treatment responses have been strengthened and randomised controlled trials with novel agents (e.g. Janus kinase inhibitors) are in progress. As the main aim of effective treatment is to prevent disease progression, early diagnosis will remain an important target, as will prevention in the longer term.

Andrew G. Messenger

Leila Asfour

Matthew Harries

Frontal Fibrosing Alopecia: An Update

前额纤维性脱发：最新进展

Hidradenitis suppurativa (HS) is an inflammatory skin disorder presenting with painful and draining nodules in intertriginous areas that may progress to sinus tracts. There is an increased prevalence of obesity in HS, and obesity may predispose patients to HS. Weight loss has been associated with improvement of HS symptoms. However, weight loss through diet modification, exercise or bariatric surgery has mixed results. Recently, glucagon-like peptide-1 (GLP-1) receptor agonists have been investigated for weight loss in HS. These drugs are effective for weight loss and reduce weight-related comorbidities, with few significant side effects. Early studies of liraglutide and semaglutide in HS have demonstrated improvement in disease severity and quality of life. GLP-1 receptor agonists are a promising therapy for patients with HS and may improve symptoms through decreased mechanical stress and moderation of inflammation.

Jennifer Strong

Marcia S. Driscoll

Obesity in Hidradenitis Suppurativa: Are GLP-1 Receptor Agonists the New Frontier?

肥胖与化脓性汗腺炎：GLP-1受体激动剂是新前沿吗？

The advent of immune checkpoint inhibition has revolutionized treatment of advanced melanoma. While most patients derive survival benefit from established immunotherapies, notably monoclonal antibodies blocking cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1, a subset does not optimally respond due to the manifestation of innate or acquired resistance to these therapies. Combination regimens have proven efficacious relative to single-agent blockade, but also yield high-grade treatment toxicities that are often dose-limiting for patients. In this review, we discuss the significant strides made in the past half-decade toward expanding the melanoma immunotherapy treatment paradigm. These include newly approved therapies, adoption of neoadjuvant immunotherapy, and studies in the clinical trials pipeline targeting alternative immune checkpoints and key immunoregulatory molecules. We then review how developments in molecular and functional diagnostics have furthered our understanding of the tumor-intrinsic and -extrinsic mechanisms driving immunotherapy resistance, as well as highlight novel biomarkers for predicting treatment response. Throughout, we discuss potential approaches for targeting these resistance mechanisms in rational combination with established immunotherapies to improve outcomes for patients with melanoma.

David X. Zheng

David J. Bozym

Giuseppe Tarantino

Ryan J. Sullivan

David Liu

Russell W. Jenkins

Overcoming Resistance Mechanisms to Melanoma Immunotherapy

克服黑色素瘤免疫治疗的抗性机制

The growing field of psychodermatology examines the interplay between dermatological and psychiatric comorbidities. While current literature recognizes that cutaneous and psychiatric conditions often coexist within patients, the relationship between dysregulated inflammation and depression in patients with inflammatory skin conditions has not been thoroughly explored. This review seeks to describe the connection between cutaneous disease and depression via shared inflammatory cytokine pathways. A review of current literature was conducted, and studies addressing the co-occurrence of depression and inflammatory skin diseases were included. This review focuses on depression in patients with psoriasis, atopic dermatitis, and hidradenitis suppurativa. Studies that focused on the prevalence of depression in these populations, shared inflammatory pathways, and co-management of cutaneous and psychiatric disorders were chosen. The literature revealed a high prevalence of depression in individuals with inflammatory skin conditions compared with those without cutaneous disease. Recent studies described how proinflammatory cytokines in inflammatory skin diseases can elicit inflammation in the brain, leading to depressive symptoms. Certain subsets of cytokines that mediate inflammatory pathways were associated with both cutaneous inflammation and depression, highlighting shared pathology. Antiinflammatory medications targeting shared cytokines found reductions in both cutaneous and depressive symptoms. Practitioners have emphasized interdisciplinary approaches to treating both conditions, including psychotherapy and pharmacological methods. There is a clear association between inflammatory cutaneous diseases and depression. Co-management of these conditions, including interdisciplinary methods, is essential for patients' well-being. Future research addressing similar links between other cutaneous and psychiatric conditions could yield new treatment opportunities as well.

Olivia M. Katamanin

Isabella J. Tan

Jillian Barry

Mohammad Jafferany

Role of Inflammation and Cytokine Dysregulation in Depression in Patients with Inflammatory Skin Conditions

炎症和细胞因子失调在炎症性皮肤病患者抑郁症中的作用

acBWQ6	Am J Clin Dermatol
Journal Impact	8.80
mbqgSu	DERMATOLOGY(Q1)
xGGr6y	SCI Q1中科院 1 区

ISSN	1175-0561, 1179-1888
h-index	107
hQoIdU	医学(1区)医学皮肤病学(1区)

u9zg3I	医学生物内科学皮肤病科病理免疫学遗传学外科心理学精神科化学护理部药理学生物化学疾病药物治疗银屑病
+5d/bs	e+/GRg: Adis，uzYam8: Bimonthly，dxwaWB: journal，8x2mMQ: TY4X7V
ak9yM6	A7IHrH: 2000，sQJ/D8: 38.46%，sE9og+:3.50%， wzlKC/: 40.74%
JrpmBe	网友分享经验：>12周，或约稿
jdemjX	网友分享经验：较易

American Journal of Clinical Dermatology

uM3Gfz

sZFHBm

sZFHBm

sZFHBm

sZFHBm

Hi2Sc4

e7MLUV

XjnQ+b

Kq5Kd6

LB2xFn

XmiM++

Rosacea: New Concepts in Classification and Treatment

Diagnosis and Treatment of Rosacea Fulminans: A Comprehensive Review.

Leukonychia: What Can White Nails Tell Us?

Treatment of Porokeratosis: A Systematic Review.

Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors.

Prognostic Biomarkers in Evolving Melanoma Immunotherapy

Frontal Fibrosing Alopecia: An Update

Obesity in Hidradenitis Suppurativa: Are GLP-1 Receptor Agonists the New Frontier?

Overcoming Resistance Mechanisms to Melanoma Immunotherapy

Role of Inflammation and Cytokine Dysregulation in Depression in Patients with Inflammatory Skin Conditions